Advanced search
Add to list

AT (doxorubicin-Taxol) versus AC (doxorubicin-cyclophosphamide) as first line chemotherapy in metastatic breast cancer (MBC): A phase III study. (originally presented at ASCO 2000. Abstract 282)

(2000) ANNALS OF ONCOLOGY. 11. p.155-155
Author
Organization

Citation

Please use this url to cite or link to this publication:

MLA
PICCART, MJ, T CUFER, P BRUNING, et al. “AT (doxorubicin-Taxol) Versus AC (doxorubicin-cyclophosphamide) as First Line Chemotherapy in Metastatic Breast Cancer (MBC): A Phase III Study. (originally Presented at ASCO 2000. Abstract 282).” Annals of Oncology. Vol. 11. KLUWER ACADEMIC PUBL, 2000. 155–155. Print.
APA
PICCART, M., CUFER, T., BRUNING, P., COLEMAN, R., CALVERT, H., GAMUCCI, T., TWELVES, C., et al. (2000). AT (doxorubicin-Taxol) versus AC (doxorubicin-cyclophosphamide) as first line chemotherapy in metastatic breast cancer (MBC): A phase III study. (originally presented at ASCO 2000. Abstract 282). ANNALS OF ONCOLOGY (Vol. 11, pp. 155–155). KLUWER ACADEMIC PUBL.
Chicago author-date
PICCART, MJ, T CUFER, P BRUNING, RE COLEMAN, HA CALVERT, T GAMUCCI, C TWELVES, et al. 2000. “AT (doxorubicin-Taxol) Versus AC (doxorubicin-cyclophosphamide) as First Line Chemotherapy in Metastatic Breast Cancer (MBC): A Phase III Study. (originally Presented at ASCO 2000. Abstract 282).” In Annals of Oncology, 11:155–155. KLUWER ACADEMIC PUBL.
Chicago author-date (all authors)
PICCART, MJ, T CUFER, P BRUNING, RE COLEMAN, HA CALVERT, T GAMUCCI, C TWELVES, Luc Duchateau, L BIGANZOLI, E DONATO-DI PAOLA, C YAGUE, and R EPELBAUM. 2000. “AT (doxorubicin-Taxol) Versus AC (doxorubicin-cyclophosphamide) as First Line Chemotherapy in Metastatic Breast Cancer (MBC): A Phase III Study. (originally Presented at ASCO 2000. Abstract 282).” In Annals of Oncology, 11:155–155. KLUWER ACADEMIC PUBL.
Vancouver
1.
PICCART M, CUFER T, BRUNING P, COLEMAN R, CALVERT H, GAMUCCI T, et al. AT (doxorubicin-Taxol) versus AC (doxorubicin-cyclophosphamide) as first line chemotherapy in metastatic breast cancer (MBC): A phase III study. (originally presented at ASCO 2000. Abstract 282). ANNALS OF ONCOLOGY. KLUWER ACADEMIC PUBL; 2000. p. 155–155.
IEEE
[1]
M. PICCART et al., “AT (doxorubicin-Taxol) versus AC (doxorubicin-cyclophosphamide) as first line chemotherapy in metastatic breast cancer (MBC): A phase III study. (originally presented at ASCO 2000. Abstract 282),” in ANNALS OF ONCOLOGY, 2000, vol. 11, pp. 155–155.
@inproceedings{346915,
  author       = {PICCART, MJ and CUFER, T and BRUNING, P and COLEMAN, RE and CALVERT, HA and GAMUCCI, T and TWELVES, C and Duchateau, Luc and BIGANZOLI, L and DONATO-DI PAOLA, E and YAGUE, C and EPELBAUM, R},
  booktitle    = {ANNALS OF ONCOLOGY},
  issn         = {0923-7534},
  language     = {eng},
  pages        = {155--155},
  publisher    = {KLUWER ACADEMIC PUBL},
  title        = {AT (doxorubicin-Taxol) versus AC (doxorubicin-cyclophosphamide) as first line chemotherapy in metastatic breast cancer (MBC): A phase III study. (originally presented at ASCO 2000. Abstract 282)},
  volume       = {11},
  year         = {2000},
}

Web of Science
Times cited: